Eastern US coal and gas producer Consol Energy said Tuesday that its third-quarter coal production exceeded guidance provided in the second quarter, while margins decreased primarily as a result of lower sales prices per ton. Consol said ...
Tags: coal, gas, Metallurgy, Mineral, Energy
Navistar International's losses continue to mount, though the company says its order board is strengthening and the addition of the Cummins ISB mid-range engine sets its medium-duty business up for a turnaround. The company this morning ...
Tags: Transportation, Auto Parts
Insulet, a provider of tubeless insulin pump technology, has reported a net loss of $12.42m, or $0.26 per share, for the third quarter ended 30 September 2012 compared to a net loss of $13.56m, or $0.29 per diluted share, for the third ...
Tags: Insulet, tubeless insulin pump technology, Financial situation
Navidea Biopharmaceuticals has reported a net loss attributable to common stockholders of $9.12m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net income attributable to common stockholders of $19.81m, or ...
Tags: Navidea Biopharmaceuticals, common stockholders, radiopharmaceutical
EpiCept has reported a net loss of $1.13m, or $0.03 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.40m, or $0.08 per share, for the same period in 2011. Loss from operations for the third quarter of ...
Tags: Net Loss, merger partner, operating loss
Galena Biopharma has reported a net loss of $6.26m, or $0.09 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.47m, or $0.09 per share, for the third quarter ended 30 September 2011. Operating loss for ...
Tags: Net Loss, operational and business development, patient enrollment
Sophiris Bio has reported a net loss of $5.62m, or $0.03 per share, for the third quarter ended 30 September 2012 compared to a net loss of $2.97m, or $0.02 per share, for the third quarter ended 30 September 2011. Expenses for third ...
Tags: Sophiris Bio, net loss, Q3 Net Loss, PRX302 clinical program
Keryx Biopharmaceuticals has reported a net loss of $5.47m, or $0.08 per share, for the third quarter ended 30 September 2012 compared to a net loss of $10.25m, or $0.15 per share, for the third quarter ended 30 September 2011. Operating ...
Tags: Net Loss, Biopharmaceuticals, top-line data
Novavax has reported a net loss of $7.22m, or $0.05 per share, for the third quarter ended 30 September 2012 compared to a net loss of $3.21m, or $0.03 per share, for the third quarter ended 30 September 2011. Revenue for third quarter of ...
Tags: Novavax, Wider Q3 Net Loss, net loss, clinical trials
Immunovaccine has reported a net loss of $1.7m for the third quarter ended 30 September 2012 compared to a net loss of $1.5m for the same quarter in 2011. According to the company the increased loss is due to the $155,000 increase in ...
Tags: Net Loss, therapeutic cancer vaccine, immune enhancement technology
Curis, a drug development company, has reported a net loss of $3.38m, or $0.04 per share, for the third quarter ended 30 September 2012 compared to a net loss of $4.21m, or $0.05 per share, for the third quarter ended 30 September 2011. ...
Tags: Net Loss, proprietary and licensed programs, clinical trial
Inovio Pharmaceuticals has reported a net loss attributable to the company of $6.62m, or $0.05 per share, for the third quarter ended 30 September 2012 compared to a net loss attributable to the company of $4.54m, or $0.04 per share, for ...
Tags: Inovio Pharmaceuticals, Loss Increases, loss attributable
Albany Molecular Research (AMRI) has reported a net loss of $2.14m, or $0.07 per share, for the third quarter ended 30 September 2012 compared to a net loss of $5.85m, or $0.19 per share, for the third quarter ended 30 September 2011. ...
Clinical stage drug development company Telik has reported a net loss of $1.88m, or $0.78 per share, for the third quarter ended 30 September 2012 compared to a net loss of $2.85m, or $1.58 per share, for the third quarter ended 30 ...
Tags: Clinical stage drug development, net loss, loss from operations